Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Long-Term Investments (2022 - 2025)

Indivior Pharmaceuticals has reported Long-Term Investments over the past 4 years, most recently at $28.0 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $28.0 million for Q4 2025, up 3.7% from a year ago — trailing twelve months through Dec 2025 was $28.0 million (up 3.7% YoY), and the annual figure for FY2025 was $28.0 million, up 3.7%.
  • Long-Term Investments for Q4 2025 was $28.0 million at Indivior Pharmaceuticals, roughly flat from $28.0 million in the prior quarter.
  • Over the last five years, Long-Term Investments for INDV hit a ceiling of $98.0 million in Q4 2022 and a floor of $27.0 million in Q4 2024.
  • Median Long-Term Investments over the past 4 years was $28.0 million (2025), compared with a mean of $39.4 million.
  • Biggest five-year swings in Long-Term Investments: tumbled 58.16% in 2023 and later grew 3.7% in 2025.
  • Indivior Pharmaceuticals' Long-Term Investments stood at $98.0 million in 2022, then tumbled by 58.16% to $41.0 million in 2023, then crashed by 34.15% to $27.0 million in 2024, then grew by 3.7% to $28.0 million in 2025.
  • The last three reported values for Long-Term Investments were $28.0 million (Q4 2025), $28.0 million (Q3 2025), and $27.0 million (Q2 2025) per Business Quant data.